Respiratory diseases are second only to cardiovascular conditions in terms of mortality, incidence and costs. Among the most frequent causes of respiratory death in Europe are pneumonia and chronic obstructive pulmonary disease (COPD). Hundreds of millions of people suffer from chronic respiratory ill-health every day worldwide.  According to the World Health Organisation (WHO) global estimates, 300 million people have asthma, 210 million people have COPD, while millions more have allergic rhinitis and other, often under-diagnosed, chronic respiratory conditions.

Climate change is likely to have mostly adverse effects on health. These findings have been well described by the WHO. In Europe, as elsewhere, deaths from chronic respiratory and lung conditions are expected to increase in the future.

Despite the fact that emphysema and asthma often have no cure, nebulized solutions Yabro® a Yabro® Spray – sol containing Hyaluronic Acid are helpful in the treatment of the main symptoms and – acting as an adjuvant therapy – they may reduce the need for bronchodilators; together with other more specific medications for each of the condition considered, this treatment is effective in both the upper and lower airways, narrowing and widening the flow of air to and from the lungs. Hyaluronic acid is the body's own substance and is a natural part of the tissues of the respiratory system. It has several natural functions in the organism and contributes to maintaining the balance of the internal part of the organism. Its therapeutic use is not associated with the risk of adverse effects, interactions with other concurrent treatment of the disease are not described and it can be used by both children and adults.

Yabro® contains 0.3% hyaluronic acid for inhalation treatment. It is transformed into an aerosol by a compressor inhaler. Yabro® Spray – sol is a spray solution for topical application of hyaluronic acid to the upper airways with a special applicator. The Spray-sol application tool sprays hyaluronic acid with the optimal size of particles ideal for nasal administration. Thanks to its regeneration properties, hyaluronic acid is used after surgeries (e.g. in paranasal sinuses) and improves post-surgical healing of the mucosa.

Rhinitis is another condition in which it is helpful to use nebulized Hyaluronic Acid in combination with isotonic seawater solution Aliamare®. It is used in the allergic type of rhinitis together with other medicaments such as antihistaminics and corticosteroids. After topical nasal administration, hyaluronic acid rapidly penetrates through the tissues of the respiratory system and becomes part of the intercellular mass. Thanks to its effect, the natural immunity of the mucosa is increased, the airway tissues are hydrated and their ability to regenerate is increased. In the case of nasal administration, hyaluronic acid also contributes to faster clearing of the airways of mucus, dirt and allergens.

Aliamare® is a combination of 0.2% hyaluronic acid and isotonic seawater in spray for daily hygiene and treatment of upper respiratory diseases for children from 1 month of age and for adults.

Aliamare® suppresses thin nasal discharge, helps with acute chronic rhinitis and allergies. It speeds up the healing of damaged mucosa (micro-cracks), reduces the formation of protrusions and helps to remove them. It the mucosa moist and prevents its drying. It prevents bacteria and viruses from attaching to the mucosa. It relieves swelling and burning of the nasal mucosa.

Aliamare® Clean are 5 ml ampoules with 100% sterile content of isotonic seawater. They are suitable and safe for babies from birth for daily cleaning and rhinitis. Babies cannot breathe through their mouth during the first months of their lives, so it is essential for them to have a clean and clear nose. With a clogged nose, not only can they not breathe well, but also cannot drink, which is essential for their well-being.

Isotonic seawater in Aliamare® Clean has the same concentration of salts as human body cells and does not damage them.

It is naturally rich in trace elements and mineral salts. Filtered seawater comes from the Bréhat island in Brittany and is known for its anti-inflammatory effects.

Available over-the-counter forms of hyaluronic acid medical devices:
YABRO®, nebulized solution 10 x 3 ml
YABRO® Spray-sol, nebulizer set 10 x 5 ml
ALIAMARE®, nasal spray 100 ml
ALIAMARE®, nasal spray 50 ml
ALIAMARE® Clean, nasal ampoules 24 x 5 ml

On the other hand, the efficacy of N-Acetylcysteine as a mucolytic is widely known and drugs containing this active compound can cure symptoms in patients suffering from both acute and chronic bronchitis.

Solmucol® is a drug suitable for all kinds of respiratory diseases involving increased mucus production that is coughed up insufficiently, such as acute and chronic bronchitis, bronchial asthma, sinusitis, laryngitis (larynx inflammation), trachitis and influenza. It is also suitable as a complementary treatment of chronic diseases, such as cystic fibrosis. The active substance N-Acetylcysteine dissolves mucus in the airways and facilitates expectoration. As a result, the mucus is diluted and easier to remove by expectoration or blowing the nose. In addition, Solmucol supports the self-cleaning abilities of lungs, is anti-oxidizing and anti-inflammatory with detoxification properties. Recent clinical studies have shown the effect of N-Acetylcysteine on influenza and influenza-like diseases and its antibacterial properties.

Solmucol® is free of colourings, lactose and gluten. It is also alcohol and sugar free, so it is suitable for diabetics.

Available over-the-counter pharmaceutical forms:
SOLMUCOL 180, syrup 1x180 ml
SOLMUCOL 90, syrup 1x90 ml
SOLMUCOL pastilles 100 mg, 24x100 mg
SOLMUCOL 100 mg, granulate 20 x 100 mg
SOLMUCOL 200 mg, granulate 20 x 200 mg
SOLMUCOL 600 mg, granulate 7 x 600 mg

NB: the information in the products contained on this website and the sections on specific health issues are for information purposes only and are meant to encourage and not replace the relationship between Doctor and Patient. The indications provided are of a general nature: personalised cures and therapies must be prescribed exclusively by Medical Practitioners.